|
GB202102049D0
|
|
Viruses
|
|
GB201916292D0
|
|
Viruses
|
|
GB201909081D0
|
|
Method
|
|
GB201812100D0
|
|
Method
|
|
WO2018220207A1
|
|
Oncolytic virus and method
|
|
GB201801615D0
|
|
Method
|
|
GB201801614D0
|
|
Formulation
|
|
WO2018083259A1
|
|
Oncolytic adenovirus encoding transgenes
|
|
WO2018083258A1
|
|
Oncolytic adenovirus encoding at least three transgenes
|
|
WO2018083257A1
|
|
Oncolytic adenovirus encoding transgenes
|
|
US2019194690A1
|
|
Adenovirus armed with bispecific t cell engager (bite)
|
|
GB201713765D0
|
|
Modified adenovirus
|
|
GB201708778D0
|
|
Virus and method
|
|
GB201708779D0
|
|
Virus and method
|
|
GB201706219D0
|
|
Modified adenovirus
|
|
GB201700663D0
|
|
Modified adenovirus
|
|
BR112018012179A2
|
|
group b adenovirus encoding an anti-tcr antibody or fragment complex
|
|
GB201614607D0
|
|
Modified adenovirus
|
|
SG10201803081TA
|
|
Oncolytic adenovirus encoding a b7 protein
|
|
GB201607463D0
|
|
Method
|
